Pharma BD Deal Intelligence

Novartis AG / PTC Therapeutics Inc.

2024 · Licensing/Option · $2.9B · Complete

A $2.9B Novartis licensing deal for PTC518 (votoplam), an oral Huntington's disease splicing modifier, with $1B upfront and a $50M milestone triggered by Phase 3 dosing. Phase 3 INVEST-HD is now underway, backed by PIVOT-HD interim data showing dose-dependent slowing of disease progression (52% at 10mg).

CALLED IT — OFF BY 3
Full analysis, sources & comparables →

The coverage arc

Mar 24, 2026 ClinicalTrials.gov (NCT07326709) Neutral

Phase 3 INVEST-HD: randomized, placebo-controlled study of votoplam in Huntington's disease; sponsor Novartis; ~770 participants; start 2026-03-24; primary…

Apr 28, 2026 PTC Therapeutics Bullish

Month-24 PIVOT-HD LTE: dose-dependent slowing on cUHDRS in Stage 2 HD (52% at 10mg, 28% at 5mg) vs natural-history cohort; votoplam = former PTC518.

May 07, 2026 PTC Therapeutics Bullish

First patient dosed in Phase 3 INVEST-HD study, triggering $50 million milestone payment from Novartis to PTC in Q2 2026.

Source summaries from our enrichment pipeline; follow links for originals.

All 7 sources with sentiment breakdown →

Novartis licensed PTC518 (now votoplam), an oral small-molecule HTT-lowering splicing modifier for Huntington's disease then in Phase II, paying $1B upfront in a deal worth up to $2.9B. The license closed March 31, 2025, after which Novartis assumed development, manufacturing and commercialization. Novartis advanced the program into the global Phase 3 INVEST-HD study (~770 early HD patients, cUHDRS at Month 36), dosing its first patient in Q2 2026 and triggering a $50M milestone payment to PTC. Phase 3 was supported by the Month-24 PIVOT-HD long-term-extension interim, which showed dose-dependent slowing of disease progression on cUHDRS (52% at 10mg, 28% at 5mg) vs. natural-history controls.

Key facts

Disease & market context

Huntington Disease

Competitive Landscape

Huntington's disease (HD) has no disease-modifying therapy approved; PTC518 is an oral HTT-lowering splice modulator entering a field of failed prior candidates. Oral HTT splice modulators (PTC518's direct MOA): PTC Therapeutics' PTC518 (Phase 2 PIVOT-HD, 12-month data showed dose-dependent HTT lowering in blood/CSF) is first-in-class oral; no direct oral competitor at equivalent stage. Intrathecal antisense oligonucleotides (ASO — adjacent MOA): Roche/Ionis's tominersen (RG6042/IONIS-HTTRx, Phase 3 GENERATION HD1 halted 2021 for futility/harm, relaunched GENERATION HD2 Phase 2 2022 in lower-burden patients); Wave Life Sciences' WVE-003 (SNP3 allele-selective, Phase 1b/2a SELECT-HD showing mHTT lowering). RNAi/gene therapy (one-time intraparenchymal — adjacent MOA): uniQure's AMT-130 (AAV5-miRNA, Phase 1/2 showing slower disease progression in high-dose cohort, 2024 interim update) is the lead gene therapy; Spark/Roche and Voyager had earlier programs. Symptomatic/chorea SOC (incumbent): Teva's Austedo (deutetrabenazine, VMAT2 inhibitor, approximately $1.6B 2024 sales across HD chorea and tardive dyskinesia) and Lundbeck/Bausch's Ingrezza/Xenazine (valbenazine/tetrabenazine, VMAT2) manage chorea only. Antipsychotics and SSRIs are used off-label for psychiatric symptoms. For a commercial lead, PTC518's oral administration is a major commercial differentiator vs. intrathecal tominersen or AAV-delivered AMT-130 — Novartis's $2.9B bet prices in category leadership if Phase 3 establishes disease modification.

Deal timeline

Related deals — scored

DealYearValueOutcome
Novartis AG / PTC Therapeutics Inc. (this deal)2024$2.9B80
Novartis AG / Advanced Accelerator Applications S.A.2017$3.9B98
Novartis AG / Endocyte, Inc.2018$2.1B96
Novartis AG / Lek Pharmaceuticals d.d.2002$876M88
Novartis AG / GlaxoSmithKline plc2014$16.0B81
Novartis AG / Chinook Therapeutics Inc.2023$3.5B78
Novartis AG / Hexal AG2002$8.3B75

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →